Corcept Therapeutics Shows Lifyorli Overall Survival Benefit in Platinum-Resistant Ovarian Cancer at ASCO 2026
Corcept Therapeutics Reports Statistically Significant Overall Survival Benefit for Lifyorli in Platinum-Resistant Ovarian Cancer at ASCO 2026 Corcept Therapeutics Incorporated, a commercial-stage biopharmaceutical company focused on discovering and developing therapies…
Veracyte OPTIMA Trial Shows Prosigna Identifies Breast Cancer Patients Who Can Avoid Chemotherapy
Veracyte’s Prosigna Test Shows Practice-Changing Results in Early Breast Cancer at ASCO 2026 OPTIMA Trial Veracyte, Inc., a leading cancer diagnostics company, has announced highly significant results from the independent…
Virion Therapeutics Reports Durable HBV Functional Cure Signals with HBsAg Decline at EASL 2026
Virion Therapeutics Reports Durable Functional Cure Signals in Chronic Hepatitis B with Single-Dose VRON-0200 at EASL 2026 Virion Therapeutics, LLC, a clinical-stage biotechnology company focused on developing next-generation T cell–based…
Beren Therapeutics Announces Six Presentations at 2026 APMRF Conference
Beren Therapeutics to Present Comprehensive Adrabetadex Data at 2026 NPC Research Conference, Highlighting Early Treatment Benefits and Mechanistic Insights Beren Therapeutics P.B.C., the parent company of Mandos LLC and a…
Bristol Myers Squibb Mezigdomide Cuts Myeloma Progression Risk by Over 50%
Bristol Myers Squibb’s Mezigdomide Combo Shows Strong Phase 3 Success in Relapsed Multiple Myeloma at ASCO 2026 Bristol Myers Squibb has announced encouraging late-breaking results from the Phase 3 SUCCESSOR-2…
PanTher Completes Phase 1b Dose Escalation in Non-Metastatic Pancreatic Cancer and Appoints Tim Clackson to Board of Directors
PanTher Therapeutics Advances PTM-101 with Phase 1b Dose Escalation Completion in Pancreatic Cancer and Appoints Oncology Veteran Tim Clackson to Board PanTher Therapeutics, a clinical-stage biotechnology company developing implant-based localized…
Canopy Growth Reintroduces Tweed Brand in Germany with New MTL Cannabis Lineup, First Post-Acquisition Global Launch
Canopy Growth Relaunches Tweed Brand in Germany and Expands Medical Cannabis Portfolio Following MTL Acquisition Canopy Growth Corporation has announced a major strategic milestone in its international expansion strategy with…
Meiji Seika Pharma Invests in GHIC Global Health Security Fund
Meiji Seika Pharma Invests in Global Health Security Fund to Advance Pandemic Preparedness and Infectious Disease Innovation Meiji Seika Pharma Co., Ltd., one of Japan’s leading pharmaceutical companies with a…
Merck’s Calderasib Receives FDA Breakthrough Therapy Designation for KRAS G12C-Mutant Non-Small Cell Lung Cancer
Merck’s Investigational KRAS Inhibitor Calderasib Receives FDA Breakthrough Therapy Designation for First-Line KRAS G12C-Mutated Lung Cancer Merck, known as MSD outside the United States and Canada, has announced a significant…
BeOne Medicines Highlights 78-Month BRUKINSA Data Demonstrating Sustained Disease Control in CLL at ASCO 2026
BeOne Medicines Showcases Long-Term BRUKINSA Success and Next-Generation CLL Treatment Advances at ASCO 2026 BeOne Medicines Ltd., a global oncology company dedicated to developing innovative cancer therapies, is presenting extensive…
CorWave Secures ISO 13485 Certification, Advancing Commercialization of Cardiac Assist Devices
CorWave Achieves ISO 13485 Certification, Advancing Commercialization Plans for Innovative Heart Failure Devices CorWave, a clinical-stage medical technology company focused on developing next-generation cardiac assist devices, has announced a significant…
IMFINZI Approved in U.S. as First Immunotherapy Combination for High-Risk NMIBC
IMFINZI® (durvalumab) Becomes First Approved Immunotherapy Combination in the U.S. for Patients with BCG-Naïve High-Risk Non-Muscle-Invasive Bladder Cancer AstraZeneca has secured a significant new regulatory milestone for its immunotherapy IMFINZI…